SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing…
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided…
International Society for Cell & Gene Therapy (ISCT) Names Dr. Lowdell with the Career Achievement Award in Cell and Gene Therapy…
Designed to Streamline Ordering, Payment Processing, and Reimbursement SubmissionsMARIETTA, Ga., March 13, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq:…
New pharmacokinetic data demonstrate Virtue® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without…
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2…
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE…
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in…
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private…
Elimination of Remaining Debt to Perceptive Advisors Leaves the Company’s Balance Sheet Debt FreePRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE)…